CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Imetelstatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01731951
NCT01731951Phase 2Completed
CompareCT.gov

A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies

Geron Corporation·interventional·Posted Nov 22, 2012·Updated Sep 21, 2021

In Brief

A Phase 2 clinical trial evaluating Imetelstat for Primary Myelofibrosis and 2 related conditions. Completed, enrolled 80 participants across 1 site.

Detailed Summary

This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 22, 2012
Enrollment StartOct 29, 2012
Primary CompletionMay 24, 2018
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 13.6 years ago

Interventions

Imetelstatdrug

Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.